Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies

After myocardial infarction (MI), patients are at a greater risk of heart failure. Post-MI patients with left ventricular systolic dysfunction have a higher risk of mortality or morbidity. Strong and compelling data from randomized trials have demonstrated that drug therapies intended for preventing post-MI remodeling with neuro-hormonal inhibitors can considerably improve short- and long-term outcomes, including death, reinfarction, and worsening heart failure. This article aims at summarizing clinical data on established pharmacological therapies in treating post-MI patients with or without left ventricular systolic dysfunction (LVSD), and with or without signs and symptoms of heart failure.